SynthesisBMJ open2024
Association between non-alcoholic fatty liver disease and risk of sarcopenia: a systematic review and meta-analysis.
Synthesis in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07598916 (Sarcopenia Among Patients With Metabolic Dysfunction-associated Steatotic Liver Disease), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Sarcopenia Among Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
Who cites it
11 citing papers in PubMed.
- Hepatokines lipocalin 2 and osteopontin drive muscle atrophy in MASH.Molecular metabolism · 2026Article
- Sarcopenia and MASLD: novel insights and the future.Nature reviews. Endocrinology · 2026Review
- Quercetin alleviates metabolic-associated fatty liver disease by tuning hepatic lipid metabolism, oxidative stress and inflammation.Animal biotechnology · 2025Article
- Clinical significance and pathogenic mechanisms of fatigue in metabolic dysfunction-associated steatotic liver disease.World journal of hepatology · 2025Review
- Review
- Metabolic Dysfunction-Associated Steatotic Liver Disease as a Risk Factor for Chronic Kidney Disease: A Narrative Review.Biomedicines · 2025Review
- Skeletal muscle and MASLD: Mechanistic and clinical insights.Hepatology communications · 2025Review
- Metabolic dysfunction-associated steatotic liver disease: A story of muscle and mass.World journal of gastroenterology · 2025Article
- Non-Alcoholic Fatty Liver Disease in Everyday Clinical Practice: From Diagnosis to Therapy.Life (Basel, Switzerland) · 2025Article
- Impact of steatotic liver disease subtypes, sarcopenia, and fibrosis on all-cause and cause-specific mortality: a 15.7-year cohort study.BMC gastroenterology · 2025Article
- ROS-responsive MnOTheranostics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo determine the association of non-alcoholic fatty liver disease (NAFLD) with the incidence of sarcopenia.
designSystematic review and meta-analysis of observational clinical studies. SETTING AND
participantsAdults with NAFLD.
methodsDatabases such as PubMed, Embase, Cochrane and Web of Science were searched for eligible studies published from the inception of each database up to 4 April 2023. All cross-sectional studies on the association between NAFLD and sarcopenia were included in this study. The quality of the included studies and risk of bias was assessed using the Agency for Healthcare Research and Quality checklist. STATA V.15.1 software was used for statistical analysis.
resultsOf the 1524 retrieved articles, 24 were included in this review, involving 88 609 participants. Our findings showed that the prevalence of sarcopenia was higher in the NAFLD group than in the control group (pooled OR 1.74, 95% CI 1.39 to 2.17). In a subgroup analysis by region, patients with NAFLD showed an increased risk of sarcopenia (pooled OR 1.97, 95% CI 1.54 to 2.51) in the Asian group, whereas patients with NAFLD had no statistically significant association with the risk of sarcopenia in the American and European groups, with a pooled OR of 1.31 (95% CI 0.71 to 2.40) for the American group and a pooled OR of 0.99 (95% CI 0.21 to 4.69) for the European group. Similar results were observed in the sensitivity analysis, and no evidence of publication bias was observed. CONCLUSIONS AND IMPLICATIONS: The current study indicated a significant positive correlation between NAFLD and sarcopenia, which may be affected by regional factors. This study provides the correlation basis for the relationship between NAFLD and sarcopenia and helps to find the quality strategy of sarcopenia targeting NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.